HGSI: Summary for Human Genome Sciences, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 5:42am EST - Canadian Markets open in 3 hours and 48 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Human Genome Sciences Inc. (HGSI)

On Feb 9: 27.06 USD 0.00 (0.00%)

MORE ON HGSI

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Human Genome Sciences, Inc. (NGM:HGSI) Delayed quote data

Last Trade:	27.06 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	27.06
Open:	N/A
Bid:	24.91 x 100
Ask:	27.99 x 100
1y Target Est:	34.47

Day's Range:	N/A - N/A
52wk Range:	0.45 - 32.07
Volume:	0
Avg Vol (3m):	4,153,480
Market Cap:	4.47B
P/E (ttm):	N/A
EPS (ttm):	-0.16
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add HGSI to Portfolio

Download Data

HEADLINES

•	UK court overturns GSK patent for lupus drug
	at FT.com (Tue 6:10pm)

•	UK court rules HGS gene patent invalid -lawyers
	at Reuters (Tue 11:39am)

•	Biotech ETFs Immune To Broad Selling
	Investor's Business Daily (Mon, Feb 8)

•	[$$] Biotech ETFs Are Looking Healthy
	at RealMoney by TheStreet.com (Mon, Feb 8)

•	Friday Options Recap: Defensive Trading
	at Seeking Alpha (Fri, Feb 5)

•	Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BIO CEO Investor Conference
	Business Wire (Fri, Feb 5)

•	Glaxo Brings Home the Bacon
	at Motley Fool (Thu, Feb 4)

•	The Answer You've Been Waiting For
	at Motley Fool (Wed, Feb 3)

•	3 Best Hedge Fund Healthcare Ideas
	at Seeking Alpha (Wed, Feb 3)

•	Human Genome Sciences Names Scott Habig Vice President, Sales
	Business Wire (Mon, Feb 1)

•	Critical Alerts for Potash Corp of Saskatchewan, PNC, TD Ameritrade, JC Penney, and Human Genome Sciences Released by Seven Summits Research
	PRNewswire (Fri, Jan 29)

•	Research And Development Expenditures In Diagnostic And Lab Equipment Sector Raises Capital Requirements: Will Acquisitions By Larger Health Care Companies Be The Result?
	Wall Street Transcript (Wed, Jan 27)

More Headlines for HGSI...

ANALYST

EPS Est (next year) (Dec-09) :	0.03
EPS Est (in 2 years) (Dec-10) :	-0.81
Avg Rec (current)*:	1.7
PEG Ratio:	178.33

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The companys clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer.

Full Company Profile

Add to Portfolio

Email to a Friend

•